Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simpeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Gastroenterology:
5 Current Treatments for Ulcerative Colitis
New Test Offers Promise of Simpler Celiac Disease Diagnosis
5 Things to Know About Advances in Oral Treatment for Hepatitis C
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
